News

Alstom Secures Major Contract for M-9A Railcars at €2 Billion

Alstom Secures Major Contract for M-9A Railcars at €2 Billion

Alstom Wins €2.0 Billion Order for M-9A Railcars

Alstom, a global leader in smart and sustainable mobility, has recently announced a significant contract valued at €2.0 billion with the New York Metropolitan Transportation Authority. This substantial order highlights Alstom's commitment to advancing public transport solutions.

Details of the Contract

The deal involves the supply of M-9A railcars, intended for the Long Island Rail Road and Metro-North Railroad. This contract is set to greatly enhance the efficiency and sustainability of these transit lines. Alstom aims to ensure that these vehicles are integrated smoothly into existing rail services.

Commitment to Sustainability

At the heart of Alstom's mission is the dedication to sustainable and innovative transportation. They are committed to contributing to a low carbon future by pioneering high-quality transportation solutions. This includes a wide range of products from high-speed trains to local transit, ensuring that the infrastructure supports an environmentally friendly approach to travel.

Overall Impact on Public Transport

The incoming M-9A railcars will not only modernize the fleet but also improve passenger experience through enhanced safety and comfort features. Passengers can look forward to more efficient services that align with Alstom’s vision of sustainable urban mobility.

Alstom’s Global Presence

With operations in 63 countries and a workforce of over 86,000 dedicated professionals, Alstom remains at the forefront of innovation in transport solutions. Their broad portfolio includes various transportation systems, services, and digital mobility technologies.

Company Performance Insights

Alstom generated impressive sales figures of €18.5 billion for the fiscal year ending on March 31, 2025. These results underscore Alstom's strong performance and its role as a pivotal player in the transportation sector.

Contact Information

For those interested in further information regarding this project or company insights, they can contact Alstom’s Investor Relations team. Below are the details:

Contact Details

Cyril GUERIN: +33 (0)6 07 89 36 16
cyril.guerin@alstomgroup.com

Guillaume GAUVILLE: +44 (0)7 588 022 744
guillaume.gauville@alstomgroup.com

Estelle MATURELL ANDINO: +33 (0)6 71 37 47 56
estelle.maturell@alstomgroup.com

Jalal DAHMANE: +33 (0)6 98 19 96 62
jalal.dahmane@alstomgroup.com

Frequently Asked Questions

What is the value of Alstom's recent order for M-9A railcars?

The order is valued at €2.0 billion.

Which authorities are receiving the M-9A railcars?

The M-9A railcars will be supplied to the New York Metropolitan Transportation Authority for the Long Island Rail Road and Metro-North Railroad.

What does Alstom aim to achieve with this order?

Alstom aims to enhance public transport efficiencies and contribute to sustainable urban mobility.

How many countries does Alstom operate in?

Alstom operates in 63 countries worldwide.

What was Alstom's sales figure for the fiscal year 2025?

Alstom generated sales of €18.5 billion for the fiscal year ending on March 31, 2025.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 154

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
ManuTech Center Set to Revolutionize Manufacturing Hub

Updated Category News Views 207

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 22

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 148

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 225

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 155

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 150

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 233

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
les" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles